Expression and Prognostic Significance of and in Liver Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Aug 8

PMID 28781668

Citations 13

Authors

Dafei Xie

Peiwen Yuan

Dong Wang

Hua Jin

Hui Chen

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to investigate the expression of and in liver cancer, and examine the correlations with pathological parameters and prognosis. We collected tumors and tumor-adjacent normal tissue from 70 patients with liver cancer admitted to the Department of General Surgery of Zhejiang Hospital. The expression of by RT-qPCR was significantly lower in liver cancer tissues than that in the tumor-adjacent normal tissues, and the low expression was correlated with the lymphatic metastasis and TNM stage. By contrast, the expression of was significantly higher in liver cancer than that in the tumor-adjacent tissues, and the high expression was correlated with the lymphatic metastasis and TNM stage. The overall 5-year survival rate of patients was 12.9% (9/70). Single-factor survival analysis revealed that and were the factors affecting the overall survival rate of liver cancer (P<0.05) and multivariate survival analysis by Cox proportional hazards model showed that and were the independent factors affecting the survival time of patients with liver cancer. Low expression of and high expression of are closely correlated with the occurrence and development of liver cancer, especially lymphatic metastasis and TNM stage. Thus, and can serve as reference biomarkers for guiding the treatment of liver cancer and for estimating prognosis.

Citing Articles

Independent prognostic significance of tissue and circulating microrna biomarkers in hepatocellular carcinoma.

Jeng L, Chan W, Teng C Discov Oncol. 2025; 16(1):281.

PMID: 40056315 PMC: 11890906. DOI: 10.1007/s12672-025-02043-y.

Tristetraprolin Family Members and Processing Bodies: A Complex Regulatory Network Involved in Fatty Liver Disease, Viral Hepatitis and Hepatocellular Carcinoma.

Gellee N, Legrand N, Jouve M, Devaux P, Dubuquoy L, Sobolewski C Cancers (Basel). 2025; 17(3).

PMID: 39941720 PMC: 11815756. DOI: 10.3390/cancers17030348.

Lipophagy and epigenetic alterations are related to metabolic dysfunction-associated steatotic liver disease progression in an experimental model.

Schutz F, Longo L, Keingeski M, Filippi-Chiela E, Uribe-Cruz C, Alvares-da-Silva M World J Hepatol. 2025; 16(12):1468-1479.

PMID: 39744199 PMC: 11686535. DOI: 10.4254/wjh.v16.i12.1468.

Possible Role of miR-375-3p in Cervical Lymph Node Metastasis of Oral Squamous Cell Carcinoma.

Saika M, Nakashiro K, Tokuzen N, Shirai H, Uchida D Cancers (Basel). 2024; 16(8).

PMID: 38672573 PMC: 11049256. DOI: 10.3390/cancers16081492.

Dysregulation of miRISC Regulatory Network Promotes Hepatocellular Carcinoma by Targeting PI3K/Akt Signaling Pathway.

Kannan M, Jayamohan S, Moorthy R, Chabattula S, Ganeshan M, Arockiam A Int J Mol Sci. 2022; 23(19).

PMID: 36232606 PMC: 9569668. DOI: 10.3390/ijms231911300.

References

Tang W, Zhu J, Su S, Wu W, Liu Q, Su F . MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One. 2012; 7(12):e51702. PMC: 3519894. DOI: 10.1371/journal.pone.0051702. View

Yang J, Roberts L . Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010; 24(4):899-919, viii. PMC: 3949429. DOI: 10.1016/j.idc.2010.07.004. View

Panera N, Gnani D, Crudele A, Ceccarelli S, Nobili V, Alisi A . MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20(41):15079-86. PMC: 4223241. DOI: 10.3748/wjg.v20.i41.15079. View

He X, Guo A, Xu C, Chang Y, Xiang G, Gong J . Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties. Oncol Rep. 2014; 32(3):1200-10. DOI: 10.3892/or.2014.3306. View

Li Y, Jiang Q, Xia N, Yang H, Hu C . Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res. 2012; 40(5):1662-9. DOI: 10.1177/030006051204000505. View

Siomi H, Siomi M . On the road to reading the RNA-interference code. Nature. 2009; 457(7228):396-404. DOI: 10.1038/nature07754. View

Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H . ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 2014; 26(3):331-343. PMC: 4165611. DOI: 10.1016/j.ccr.2014.07.001. View

Yoo B, Emdad L, Su Z, Villanueva A, Chiang D, Mukhopadhyay N . Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 2009; 119(3):465-77. PMC: 2648696. DOI: 10.1172/JCI36460. View

He X, Chang Y, Meng F, Wang M, Xie Q, Tang F . MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2011; 31(28):3357-69. DOI: 10.1038/onc.2011.500. View

10.

He G, Karin M . NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2010; 21(1):159-68. PMC: 3193410. DOI: 10.1038/cr.2010.183. View

11.

Huang Y, Dai Y, Yu X, Bao S, Yin Y, Tang M . Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol. 2008; 23(1):87-94. DOI: 10.1111/j.1440-1746.2007.05223.x. View

12.

Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J . MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 2012; 57(1):299-310. DOI: 10.1002/hep.25984. View

13.

Zhu Z, Zhang X, Wang G, Zheng H . Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon. 2014; 14(8):e18672. PMC: 4199151. DOI: 10.5812/hepatmon.18672. View

14.

Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B . miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2009; 107(1):264-9. PMC: 2806773. DOI: 10.1073/pnas.0907904107. View

15.

Karagozian R, Derdak Z, Baffy G . Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014; 63(5):607-17. DOI: 10.1016/j.metabol.2014.01.011. View

16.

Duan X, Zhang L, Fan J, Qiao L . NAFLD leads to liver cancer: do we have sufficient evidence?. Cancer Lett. 2013; 345(2):230-4. DOI: 10.1016/j.canlet.2013.07.033. View

17.

Goldman R, Gruenbaum Y, Moir R, Shumaker D, Spann T . Nuclear lamins: building blocks of nuclear architecture. Genes Dev. 2002; 16(5):533-47. DOI: 10.1101/gad.960502. View

18.

Cohen M, Lee K, Wilson K, Gruenbaum Y . Transcriptional repression, apoptosis, human disease and the functional evolution of the nuclear lamina. Trends Biochem Sci. 2001; 26(1):41-7. DOI: 10.1016/s0968-0004(00)01727-8. View

19.

Griffiths-Jones S, Saini H, van Dongen S, Enright A . miRBase: tools for microRNA genomics. Nucleic Acids Res. 2007; 36(Database issue):D154-8. PMC: 2238936. DOI: 10.1093/nar/gkm952. View

20.

Kong K, Kwong D, Chan T, Law S, Chen L, Li Y . MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2011; 61(1):33-42. DOI: 10.1136/gutjnl-2011-300178. View